One main reason may be that the other feeding models—in particular CDAA-HFD—resulted in much more liver disease than HFD, as indicated by markedly higher hepatic triglyceride levels and plasma ALT levels (Figure S3e–h), and therefore a relatively smaller improvement with butyrate supplementation might not be enough to show a significant improvement in these more severe disease models. Here, GPT is linked to liver disorder.